ZEAL — Zealand Pharma A/S Share News
0.000.00%
Last trade - 00:00- DKK16.22bn
- DKK2.17bn
- DKK9.21bn
Zealand Pharma shares plunge 24% after survodutide side effects, efficacy disappoint
Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat
Brief: Zealand Pharma Says Phase 2 Zupreme-1 Trial Met Its Primary Endpoint
Zealand touts promising tolerability data for obesity drug in mid-stage study
Buyback sends Zealand Pharma up 18% after sales beat
Zealand Pharma posts smaller-than-expected Q1 loss as obesity drugs advance (updated)
Brief: Zealand Pharma Q1 EBIT Loss DKK 539 Mln
Denmark's Zealand Pharma Q1 revenue rises on obesity drug progress
Zealand Pharma posts smaller-than-expected Q1 loss as obesity drugs advance
Brief: Zealand Pharma Q1 Operating Result DKK -539 Million
Brief: Zealand Pharma Initiates $200 Mln Share Buy-Back Program
Brief: The Zealand Pharma Board Of Directors Proposes To Elect Camilla Sylvest To The Board Of Directors At An Upcoming Extraordinary General Meeting
Danish biotech firm Zealand Pharma proposes former Novo Nordisk senior to board
Brief: Zealand Pharma, Roche To Advance petrelintide To Phase 3 Trials For Chronic Weight Management
Zealand rises as survodutide shows over 16% weight loss
Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial (updated)
Brief: Zealand Pharma Says Study In Glucagon/GLP-1 Dual Agonist Survodutide Met Primary Endpoints
Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up